3 ms·
I'm somewhat familiar with industry practices (worked on software for the pharma industry) and just read 'Bad Pharma' by Ben Goldacre. It is a pretty well sourc
by sveme 13y ago
I'm somewhat familiar with industry practices (worked on software for the pharma industry) and just read 'Bad Pharma' by Ben Goldacre. It is a pretty well sourced and argued description of practices in the pharma industry and I haven't seen any worthy rebuttal of his arguments.
I'm not familiar with Marcia Angell's book, would you care to elaborate on those 'statements that boggle the mind'?
- refurb 13y agoProbably one of the better critiques of Angell's statements is Derek Lowe, an R&D chemist in the pharmaceutical industry. http://pipeline.corante.com/archives/2012/12/03/marcia_angells_interview_i_just_cant.php http://pipeline.corante.com/archives/2012/12/03/marcia_angel... I have no problem if someone disagrees with the pharmaceutical industry on a fundamental level (i.e. "there should be no profit in healthcare"), but if you start spreading misinformation and half-truths, I lose a lot of respect for that person.
- sveme 13y agoInteresting, thanks. Though not having read her book, one of the critiques seem to be that pharma companies spent a disproportionate amount on marketing and sales. And that is something I have to agree with. At the moment it looks like the industry is closing research facilities all the time one of their drugs falls from the patent cliff while keeping marketing budgets untouched. Looking at the research organization and the innovation of their approaches, I must say that they are vastly behind and extremely conservative. Novartis seems to be doing it right, though.